Panacea Biotec
Biotechnology · PANACEABIO
Small CapHealthcareDistressed / Turnaround
Dr. Rajesh Jain
Chairman and Managing Director · Visionary
Company DNA
Founder-Centric
About
Panacea Biotec is a Small Cap company in the Healthcare sector, listed on NSE as PANACEABIO. With a market cap of ₹2K Cr and revenue of ₹493 Cr, it is currently in the Distressed / Turnaround phase. Known for its Founder-Centric culture and Disruptor approach to innovation, the company operates at a Seasonal-Burst pace. Dr. Rajesh Jain remains the central authority driving the R&D and strategic turnaround efforts. Its strategic mandate: The firm requires a leadership shift to stabilize finances and streamline its R&D pipeline after prolonged periods of financial pressure.
FAQ
What kind of company is Panacea Biotec?
Panacea Biotec is a Small Cap Healthcare company (PANACEABIO) in the Distressed / Turnaround phase with a market cap of ₹2K Cr. It is classified as Founder-Centric in culture.
What is Panacea Biotec's culture and work environment like?
Panacea Biotec has a Founder-Centric culture with Disruptor innovation DNA and a Seasonal-Burst pace of execution. Employee brand: Learning Ground. Customer relationship style: B2G-Institutional. Dr. Rajesh Jain remains the central authority driving the R&D and strategic turnaround efforts.
Who leads Panacea Biotec?
Panacea Biotec is led by Dr. Rajesh Jain (Chairman and Managing Director), a Visionary leader with 20 years of experience.
What are Panacea Biotec's financials?
Panacea Biotec reported revenue of ₹493 Cr in FY25 with a 5-year revenue CAGR of -9.3%. Operating margin: -11.3%. Market cap: ₹2K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationDisruptor
PaceSeasonal-Burst
PurposeMission-First
CustomerB2G-Institutional
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleDistressed / Turnaround
Dr. Rajesh Jain remains the central authority driving the R&D and strategic turnaround efforts.
Mandate
The firm requires a leadership shift to stabilize finances and streamline its R&D pipeline after prolonged periods of financial pressure.
The firm requires a leadership shift to stabilize finances and streamline its R&D pipeline after prolonged periods of financial pressure.
Financials
Revenue FY25₹493 Cr
PAT FY25₹-83700000
Rev CAGR 5Y-9.3%
OPM-11.3%
NPM-1.7%
ROE-1%
ROCE-6%
P/E—
Fwd P/E—
P/B2.4
D/E2.8
Mkt Cap₹2K Cr
Promoter72.7%
Institutional0.1%
Similar Culture
Could You Lead Panacea Biotec?
Take the Genome Benchmark →